AbCellera CFO exercises options for 250,000 shares

AbCellera Biologics Inc.’s Chief Financial Officer Andrew Booth exercised share options to acquire 250,000 Common Shares at an exercise price of $0.19 per share.

Rhea-AI Filing Summary

AbCellera Biologics Inc.’s Chief Financial Officer Andrew Booth exercised share options to acquire 250,000 Common Shares at an exercise price of $0.19 per share. Following this transaction, he directly owns 445,600 Common Shares.

The filing also reports 130,959 Common Shares held indirectly through his spouse. The exercised options vested in substantially equal annual installments over six years, with the first tranche vesting on June 15, 2017, subject to his continuous service to the company.

Insider Trade Summary

250,000 shares exercised/converted

Exercise 3 txns

Insider Booth Andrew

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Exercise	Share option (right to buy)	250,000	$0.00	$0.00
Exercise	Common Shares	250,000	$0.19	$48K
holding	Common Shares	--	--	--

Holdings After Transaction: Share option (right to buy) — 8,501,849 contracts (Direct); Common Shares — 445,600 shares (Direct); Common Shares — 130,959 shares (Indirect, By spouse)

Footnotes (1)

1. F1. The shares subject to such option vest and become exercisable annually in substantially equal installments over a six-year period, with the first tranche vested on June 15, 2017, subject to the Reporting Person's continuous service to the Issuer on each such date.

Key Figures

Options exercised: 250,000 shares Exercise price: $0.19 per share Direct holdings after transaction: 445,600 shares +1 more

4 metrics

Options exercised 250,000 shares Common Shares acquired via option exercise on 2026-06-03

Exercise price $0.19 per share Exercise or conversion price for share options

Direct holdings after transaction 445,600 shares Common Shares directly owned by Andrew Booth after exercise

Indirect spouse holdings 130,959 shares Common Shares held indirectly through spouse

Key Terms

Form 4, share option (right to buy), derivative security, indirect ownership, +1 more

5 terms

Form 4 regulatory

"INSIDER FILING DATA (Form 4) for AbCellera Biologics Inc."

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

share option (right to buy) financial

"security_title: "Share option (right to buy)" in the derivative line"

derivative security financial

"transaction_code_description: "Exercise or conversion of derivative security""

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

indirect ownership financial

"ownership_type: "indirect" and nature_of_ownership: "By spouse""

Chief Financial Officer financial

"officer_title: "Chief Financial Officer" for reporting person Andrew Booth"

A Chief Financial Officer (CFO) is the person in charge of a company's money and financial planning. They decide how to spend, save, and invest funds to help the company grow and stay stable. Their role is important because good financial decisions keep the company healthy and successful.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did AbCellera (ABCL) CFO Andrew Booth do in this Form 4 filing?

Andrew Booth exercised share options to acquire 250,000 AbCellera Common Shares at an exercise price of $0.19 per share. After this transaction, he directly owns 445,600 Common Shares, reflecting a larger personal equity stake in the company.

At what price did AbCellera (ABCL) CFO Andrew Booth exercise his share options?

He exercised his share options at an exercise price of $0.19 per Common Share. This price comes from options that vested annually over six years, with the first vesting tranche on June 15, 2017, subject to his continuous service to AbCellera.

How many AbCellera (ABCL) shares does CFO Andrew Booth own after the reported transactions?

Following the reported transactions, Andrew Booth directly owns 445,600 AbCellera Common Shares. The filing also discloses indirect ownership of 130,959 Common Shares held by his spouse, providing additional context on his total reported economic exposure to the company’s equity.

What is the nature of the indirect AbCellera (ABCL) share ownership reported for Andrew Booth?

The filing reports 130,959 AbCellera Common Shares held indirectly, categorized as owned "By spouse." This means those shares are attributed to Andrew Booth through his spouse’s holdings, in addition to his directly held 445,600 Common Shares after the option exercise.

What does the transaction code "M" mean in AbCellera (ABCL) CFO Andrew Booth’s Form 4?

Transaction code "M" on the Form 4 indicates an exercise or conversion of a derivative security into Common Shares. In this case, Andrew Booth exercised share options to acquire 250,000 AbCellera Common Shares at an exercise price of $0.19 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/03/2026 - 02:23 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Booth Andrew

(Last) (First) (Middle)

C/O ABCELLERA BIOLOGICS INC

150 W 4TH AVENUE

(Street)

VANCOUVER

(City) (State) (Zip)

BRITISH COLUMBIA, CANADA

(Country)

2. Issuer Name and Ticker or Trading Symbol
AbCellera Biologics Inc. [ ABCL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	06/03/2026		M	V	250,000	A	$0.19	445,600	D
Common Shares								130,959	I	By spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share option (right to buy)	$0.19	06/03/2026		M	V		250,000	(1)	06/15/2026	Common Shares	250,000	$0	8,501,849	D

Explanation of Responses:

1. The shares subject to such option vest and become exercisable annually in substantially equal installments over a six-year period, with the first tranche vested on June 15, 2017, subject to the Reporting Person's continuous service to the Issuer on each such date.

Remarks:

	Tryn Stimart, attorney-in-fact	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)